How does AbbVie's $10.9 billion Apogee Therapeutics acquisition affect its 2026 profit guidance and long-term pipeline?

AbbVie agreed to acquire Apogee Therapeutics in an all-cash deal valued at approximately $10.9 billion, described as the company's largest buyout in more than five years. To fund the deal, AbbVie slightly trimmed its full-year 2026 adjusted EPS guidance, absorbing the near-term financial drag of the transaction. From a pipeline perspective, the acquisition represents a calculated bet on expanding beyond AbbVie's existing immunology and oncology assets. Apogee Therapeutics is focused on next-generation biologics for immune-mediated diseases, which suggests AbbVie is positioning to defend and extend its leadership in immunology as competitive dynamics around its current portfolio evolve over time. The near-term trade-off is lower reported profit guidance; the long-term thesis is incremental pipeline depth. For leveraged CFD positions on ABBV, this kind of binary event, large acquisition plus guidance revision, can produce sharp short-term price moves in either direction, and the 1000x leverage available on CoinUnited amplifies both potential gains and losses accordingly.

What is AbbVie's full-year 2026 revenue guidance and what products underpin that forecast?

AbbVie raised its full-year 2026 revenue guidance to approximately $67.6 billion following its second-quarter results. That figure reflects a meaningful step up from prior guidance and is underpinned largely by continued momentum in the company's immunology franchise, where strong sales drove the Q2 beat. The immunology segment has been the central revenue driver in recent periods, and the updated guidance assumes that momentum continues through the back half of the year. Oncology and neuroscience assets also contribute to the broader revenue base, though immunology remains the dominant concentration. For traders analyzing ABBV, the $67.6 billion guidance figure is a reference point against which quarterly results will be measured. Significant deviation, upward or downward, from that trajectory tends to be a catalyst for near-term price movement.

What was the FDA-approved AbbVie drug Decnupaz and what does that approval signal about the oncology pipeline?

Decnupaz is an AbbVie drug approved by the U.S. FDA for blastic plasmacytoid dendritic cell neoplasm, a very rare blood cancer. The approval targets an area of significant unmet medical need, where patient populations are small and treatment options have historically been limited. The approval signals that AbbVie is actively building out its oncology portfolio beyond its established assets, pursuing indications where it can achieve regulatory recognition for novel mechanisms in rare disease settings. Rare disease approvals, while not immediately large revenue contributors, often carry favorable pricing dynamics and can establish platform credibility for adjacent indications. For investors and traders assessing ABBV's longer-term pipeline, Decnupaz represents one data point in a broader oncology strategy. Pipeline depth matters for a company handling immunology competitive pressures, and approvals in rare blood cancers indicate the company is investing in multiple therapeutic axes simultaneously.

How does trading ABBV CFDs on CoinUnited differ from buying ABBV shares on a traditional brokerage, especially around earnings nights and M&A announcements?

Trading ABBV CFDs on CoinUnited differs from holding shares at a traditional brokerage in several material ways. Traditional brokerages typically restrict trading to exchange hours, charge commissions, and offer far more limited leverage for retail accounts. The 24/7 availability is particularly relevant for a stock like AbbVie, which releases earnings and major announcements, such as the Apogee acquisition, outside regular market hours. When AbbVie reported its Q2 2026 results and simultaneously announced the $10.9 billion acquisition, the price moved sharply in after-hours trading. A CoinUnited CFD trader could respond immediately; a traditional brokerage customer would typically wait until the next market open. The 1000x leverage means a $1,000 notional position controls $1,000,000 of ABBV exposure. This amplifies both gains and losses proportionally, and position sizing discipline becomes critical. CFDs also do not confer shareholder rights such as voting or dividend ownership in the conventional sense, which is a structural difference from direct share ownership.

What are the main risk factors for holding an ABBV leveraged position — including biosimilar competition and pipeline concentration?

The primary structural risk for AbbVie is revenue concentration. The immunology franchise accounts for a large share of total sales, meaning any disruption, biosimilar entry, pricing pressure, or clinical setbacks, has outsized impact on overall results. This concentration risk is widely discussed in pharmaceutical equity analysis and is not unique to AbbVie, but it is particularly acute given the scale of dependence on a single therapeutic category. Biosimilar competition is a specific and ongoing concern for large-molecule immunology drugs. As patents expire or are challenged, lower-cost biosimilar versions can erode branded drug market share over time. AbbVie has managed this dynamic through product transitions and geographic strategies, but the competitive clock continues. For leveraged CFD positions, these fundamental risks are compounded by the mechanics of leverage itself. At 1000x, even a modest adverse price move produces proportionally large losses relative to margin posted. Macro factors also apply: the U.S. 10-year Treasury yield was 4.63% as of mid-August 2026, and elevated rates generally compress valuations for high-multiple healthcare stocks. Pipeline concentration, specifically dependence on the Apogee acquisition to deliver long-term growth, adds execution risk that may not be reflected in near-term price action.

How does AbbVie's institutional ownership level influence its short-term price volatility and liquidity during sector rotation events?

High institutional ownership in a stock like AbbVie generally supports liquidity during normal market conditions, as large funds provide consistent two-sided order flow. However, during sector rotation events, when capital moves systematically out of healthcare into cyclicals, technology, or other categories, institutional selling can be coordinated and swift, producing sharper short-term drawdowns than fundamental news alone would warrant. AbbVie has been noted as a large-cap healthcare name attracting institutional interest, partly because sector rotation into defensive healthcare names has been observed during periods of technology-trade turbulence. This dynamic can create short-term price dislocations that are driven by macro fund flows rather than company-specific developments. For traders holding leveraged ABBV CFD positions, the implication is that volatility can spike during macro-driven rotation episodes even when AbbVie's own fundamentals are unchanged. The VIX was at 14.63 as of mid-August 2026, suggesting relatively calm broad-market conditions at that snapshot, but sector-specific volatility can diverge from headline volatility measures. Monitoring both company-specific news and macro healthcare sentiment is relevant for active position management.

How does AbbVie's immunology franchise compare to peers like Amgen and Johnson & Johnson in terms of revenue concentration risk?

AbbVie's immunology franchise is the dominant contributor to its total revenue, making it one of the more concentrated large-cap pharmaceutical revenue profiles in the sector. Peers such as Amgen and Johnson & Johnson operate across broader therapeutic portfolios, oncology, cardiovascular, consumer health, medtech, which distributes their revenue across multiple categories and reduces single-franchise dependence. This is not inherently a negative: concentration in a high-growth, high-margin category can produce strong returns when that category performs well, as AbbVie's Q2 2026 beat on immunology sales illustrates. But it does mean that competitive or regulatory developments in immunology have a more direct and immediate effect on AbbVie's financials than they would for a more diversified competitor. The Apogee acquisition and the Decnupaz oncology approval both reflect AbbVie's stated intent to diversify its pipeline beyond immunology over time. Whether those investments successfully reduce concentration risk is a multi-year question that the market will price incrementally as pipeline assets advance through clinical development and commercialization.

How are AbbVie dividends handled when trading ABBV as a CFD on CoinUnited?

Because CFD holders have price exposure rather than share ownership, AbbVie's quarterly dividend is reflected as a cash adjustment to your account — a credit if you are long, a debit if you are short — around the ex-dividend date. AbbVie has a well-established dividend history and is often cited in income-oriented research for its consecutive years of dividend growth following its 2013 spin-off from Abbott Laboratories. The practical effect for CFD traders is that long positions receive an economic equivalent of the dividend, while short positions have an equivalent amount deducted. Traders should monitor AbbVie's declared ex-dividend dates and factor the adjustment into their cost-of-carry calculations, particularly for positions held across the ex-date. CoinUnited publishes the adjustment schedule so you can see the expected credit or debit before it hits your account.

What does AbbVie's price-to-earnings (P/E) ratio tell you about how the market is valuing the stock relative to its pharma peers?

AbbVie's P/E ratio reflects the market's assessment of near-term earnings risk, particularly the ongoing transition away from Humira toward Skyrizi and Rinvoq as primary growth drivers. Large-cap pharmaceutical companies often trade at varying P/E multiples depending on pipeline depth, patent duration, and revenue concentration; AbbVie's multiple can compress or expand materially around pipeline data readouts or guidance revisions. A relatively lower P/E compared to high-growth biotech peers can indicate that the market is pricing in execution risk or revenue-cliff concerns, while expansion can signal growing confidence in the successor portfolio. Checking the trailing and forward P/E together gives a cleaner picture: AbbVie's forward multiple typically reflects analyst consensus on Skyrizi and Rinvoq ramp projections. These ratios are a starting point for relative valuation, not a standalone signal.

When are AbbVie's scheduled earnings dates, and how does volatility typically behave around those windows?

AbbVie reports quarterly earnings approximately four times per year, generally aligned with standard large-cap pharmaceutical reporting calendars — typically January, April, July, and October. Options market data historically shows implied volatility on ABBV expanding in the days before an earnings release and contracting sharply afterward, a pattern called a volatility crush. For CFD traders, this matters because wider bid-ask spreads and faster price moves are possible in the hours immediately after a report. AbbVie's results tend to be closely watched for Skyrizi and Rinvoq revenue progression, full-year guidance updates, and any pipeline commentary.

Can I trade ABBV CFDs on CoinUnited outside of U.S. stock market hours, and what gap risk should I be aware of?

Yes. CoinUnited keeps ABBV CFDs live 24 hours a day, seven days a week, which means you can open or close positions during periods when the NYSE is closed, including evenings, weekends, and holidays. However, liquidity and spreads during off-hours can differ from regular session conditions, and the CFD price is derived from reference pricing that may gap when the underlying market reopens after a period of closure. Weekend gaps are a specific concern: material news — an FDA decision, an M&A announcement, a major clinical trial result — can emerge over a Saturday or Sunday and produce a significant price difference between Friday's close and Monday's open. Holding a leveraged ABBV position over a weekend therefore carries gap risk that does not exist when you close before Friday's market close. Stop-loss orders help manage but do not eliminate this exposure.

How does leverage work for an ABBV CFD position on CoinUnited, and what triggers a liquidation?

CoinUnited offers leverage on ABBV CFDs, allowing you to control a larger notional position with a smaller margin deposit. For example, with 10x leverage, a $1,000 margin deposit would control a $10,000 notional position in ABBV. A price move of 10% against your position would in that scenario eliminate the entire margin, triggering liquidation. Liquidation occurs when your account equity falls to the maintenance margin threshold; CoinUnited's system closes the position automatically to prevent a negative balance. ABBV is not a high-frequency mover by large-cap pharma standards during normal sessions, but single-day moves of 5-10% or more have occurred around major earnings misses, surprise M&A news, or FDA decisions. Higher leverage ratios reduce the price move required to trigger liquidation, so position sizing relative to account equity is a central risk management consideration.

What is basis risk when trading ABBV as a CFD, and how closely does the CoinUnited CFD price track the NYSE-listed share price?

Basis risk is the possibility that the CFD price diverges from the underlying NYSE-quoted ABBV share price. During standard market hours, CoinUnited's ABBV CFD is priced to closely track the exchange price, with any spread representing the cost of the derivative wrapper. Outside regular hours, the CFD price is derived from reference pricing mechanisms that may not perfectly match where ABBV would open on the NYSE, creating a basis that narrows once the exchange reopens. Significant corporate events — a large block trade, a rapid news-driven spike, or a trading halt on the underlying exchange — can temporarily widen this basis. For most retail CFD use cases, the basis is small and transient, but traders holding positions through illiquid periods should be aware that the CFD closing price and the NYSE closing price may not always be identical.

What is AbbVie's dividend yield and payout history, and why do income-focused traders pay attention to it?

AbbVie has maintained and grown its dividend since separating from Abbott Laboratories in 2013, placing it among the pharmaceutical companies with longer consecutive dividend growth streaks. The yield fluctuates with the share price, so a rising share price compresses the yield even if the absolute dividend per share increases. Income-focused equity investors often cite AbbVie's dividend record as a reason for long-term holding, but CFD traders receive the economic equivalent as an adjustment rather than a formal dividend, and the yield is not a return on their leveraged margin — it is a credit proportional to the full notional value of the position. This distinction matters: a 3-4% annualized yield on a $10,000 notional CFD position translates to a far higher effective return on a $1,000 margin at 10x leverage, but that amplification cuts both ways with price movements.

Is ABBV available to trade on CoinUnited for investors outside the United States, and are there regional eligibility restrictions?

CoinUnited serves a global user base, and ABBV CFDs are generally accessible to traders in many jurisdictions where CFD trading on U.S. equities is permitted. However, regulatory requirements differ by country: some jurisdictions impose leverage caps on retail CFD accounts, others require specific risk disclosures, and a small number restrict CFD access to U.S.-listed equities entirely. Traders should review their local regulatory environment and CoinUnited's terms of service for their specific country before opening a position. Tax treatment also varies: in some regions, CFD gains are treated as capital gains; in others, as income. Because CoinUnited does not confer share ownership, certain country-specific withholding taxes on U.S. dividends may be handled differently from a direct share purchase through a local broker. Consulting a local tax advisor is recommended before trading.

How has AbbVie's revenue mix shifted since Humira lost U.S. patent exclusivity, and what does that mean for the company's near-term revenue stability?

Humira faced U.S. biosimilar competition beginning in 2023 following the expiration of its primary patent protections, and AbbVie's revenue mix has since been shifting toward Skyrizi (risankizumab) and Rinvoq (upadacitinib) as the new immunology anchors. Both drugs address conditions across immunology and inflammation and have received approvals in additional indications, which broadens their addressable markets. The transition represents a deliberate pivot that management had signaled years in advance; the pace at which Skyrizi and Rinvoq ramp up relative to Humira's decline determines the shape of AbbVie's near-term revenue trajectory. For CFD traders, understanding this mix shift helps contextualize why quarterly sales figures for Skyrizi and Rinvoq attract significant analyst attention and why guidance language around these two assets tends to move the stock.

What is AbbVie's debt profile, and does the company's leverage affect how the stock behaves during broad market rate cycles?

AbbVie carries a substantial debt load, partly inherited from its 2020 acquisition of Allergan for approximately $63 billion. The company has since worked to reduce its net debt position through operating cash flow, but it remains one of the more leveraged balance sheets among large-cap pharmaceutical companies. Higher corporate debt makes AbbVie's cost of capital more sensitive to interest rate movements: rising rates increase refinancing costs and can compress valuation multiples for high-yield-like equity structures. This means that during Federal Reserve tightening cycles, AbbVie's equity can face incremental pressure beyond what pure pipeline fundamentals would imply, while easing cycles can provide a tailwind. Monitoring AbbVie's debt maturity schedule and credit ratings gives a supplementary lens on why the stock sometimes moves in tandem with rate-sensitive sectors.

How does AbbVie's aesthetics segment — including Botox — contribute to overall revenue, and does it introduce different demand drivers than the pharmaceutical portfolio?

AbbVie acquired the aesthetics business, including the Botox Cosmetic brand, as part of the Allergan deal. This segment introduces consumer discretionary demand dynamics that differ meaningfully from prescription pharmaceutical sales: aesthetic procedure volumes are sensitive to consumer confidence, disposable income, and macroeconomic conditions in a way that immunology drugs are not. During economic slowdowns, elective cosmetic procedures can decline even when chronic disease treatments hold steady. For analysts and traders, this means AbbVie's total revenue is exposed to two distinct demand cycles simultaneously — a pharmaceutical cycle driven by patient populations and payer dynamics, and a consumer cycle driven by discretionary spending. Earnings reports often break out the Allergan Aesthetics segment separately, allowing observers to assess how each business is performing independently.

How do major FDA decisions on AbbVie pipeline assets affect intraday CFD price volatility, and how can CoinUnited's 24/7 trading help traders respond?

FDA approval decisions, complete response letters, and advisory committee votes on AbbVie pipeline or label-expansion applications can arrive at any time, including after NYSE trading hours. A positive approval can send ABBV sharply higher in after-hours trading; a rejection or a request for additional data can produce the opposite. Traders using a traditional equity brokerage face a gap between the announcement and their next opportunity to act, which may not occur until the following morning's market open. CoinUnited's 24/7 ABBV CFD trading removes that constraint, allowing a position to be opened, closed, or adjusted as soon as the news is digested. The tradeoff is that immediate post-announcement spreads can be wider than during normal hours, and rapid price moves increase liquidation risk on leveraged positions. Monitoring AbbVie's FDA action dates — published in its investor relations calendar — allows for advance awareness of when such events may occur.

Navigate to Other Instruments

ABBVAbbVie Inc.

Quick Links

Position Calculator

Position Size (USD)Leverage

Margin Required

$10.00

P&L if ABBV moves

+1%+$10.00

+5%+$50.00

+10%+$100.00

Start Trading

AbbVie Inc.

ABBV

$265.40

+1.23% (24h)

StocksTier CTradeable on CoinUnited.io1000x Leverage

Today's SignalNext earnings2026-10-29Last earnings move-2.7%2026-07-31Latest quarter revenue$16.99BQ2 2026Gross margin74.7%Q2 2026

How can you trade AbbVie Inc.? AbbVie Inc. (ABBV) is publicly listed. On CoinUnited, eligible users can trade a ABBV stock CFD — price exposure that tracks the share price. It is a price CFD, not equity (no shareholder voting; dividends reflected as an adjustment) — with extended / 24-hour trading and leverage, from US$100. Access terms vary by jurisdiction and product eligibility.

Key facts & how to trade

The essentials + how you access it on CoinUnited

Access & Tradability Comparison

A CoinUnited stock CFD vs holding the underlying shares — how, when, and in what form you get exposure. The stock price is everywhere; this comparison is the differentiator.

Terms	CoinUnited (CFD)	Holding shares (exchange)
Product form	Stock CFD (price exposure)	Equity ownership
Trading hours	Extended / 24h (by product)	Exchange regular hours
Leverage	Available (by product terms)	None / margin account needed
Shareholder rights	None (no voting; dividends as adjustment)	Voting + dividends
Access	Eligible users, by region + product	Brokerage account required

*Access and minimum vary by jurisdiction and product eligibility.

Key Facts

The most-cited facts about this company, each with its source — the quick-reference box for readers and AI answer engines.

Primary source: Wikidata

Founded	2012
Headquarters	North Chicago
CEO	Robert A. Michael
Industry	biotechnology, pharmaceutical industry
Listing status	Publicly listed: ABBVExchange
Market cap	$469B (as of 2026-08-23)CoinUnited reference x SEC shares
P/E	~112.5CoinUnited reference / SEC annual EPS
52-week range	$193.25 – $270.37CoinUnited daily kline
Next earnings	2026-10-29Finnhub
Last earnings move	-2.7% (1d), -4.8% (5d) — 2026-07-31CoinUnited daily kline
CoinUnited product	Stock CFD — price exposure, not equity (no voting; dividends reflected as adjustment); leverage available, extended/24hCoinUnited product terms

Price & Market Structure

24H Range: $260.47→$266.825

24H Low

$260.47

24H High

$266.825

BID / ASK

$265.21 / $265.6

Loading chart...

Company & financials

Business model + audited SEC financials

What Is AbbVie Inc. (ABBV)?

TL;DR

AbbVie is a large-cap U.S. pharmaceutical company anchored by immunology and oncology franchises, whose 2026 narrative is defined by strong quarterly earnings, a $10.9 billion pipeline acquisition, and a transition away from legacy product concentration.

AbbVie Inc. is a U.S.-headquartered large-cap biopharmaceutical company spun off from Abbott Laboratories, classified within the healthcare sector. Its business is organized around four primary therapeutic areas: immunology, oncology, neuroscience, and aesthetics. The immunology franchise anchors revenue generation, while oncology and neuroscience represent the primary pipeline expansion vectors.

Aesthetics, built around the Allergan acquisition, provides a differentiated consumer-facing revenue stream less correlated with traditional pharmaceutical pricing dynamics.

Corporate Scale and Revenue Architecture

As of August 2026, AbbVie ranks among the largest pharmaceutical revenue generators globally. Q2 2026 results showed revenue of $16.99 billion and adjusted earnings per share of $3.65, both ahead of consensus estimates. Revenue grew 10.2% on a reported basis and 9.5% on an operational basis in that quarter, with strong immunology drug sales identified as the primary earnings driver.

Following these results, AbbVie raised its full-year 2026 revenue guidance to approximately $67.6 billion, a scale that places it in a narrow tier of global biopharma companies capable of sustaining that level of annual sales.

For context on how AbbVie's Q2 results compared against broader multi-sector earnings trends, the Q2 Earnings Beat Blue-Chip Surge theme provides relevant framing across large-cap names reporting in the same cycle.

Pipeline Activity and Regulatory Milestones

AbbVie's oncology pipeline produced a notable regulatory milestone with the FDA approval of Decnupaz for blastic plasmacytoid dendritic cell neoplasm, a very rare blood cancer.

This approval illustrates a deliberate strategy of pursuing underserved therapeutic niches, where competitive intensity is lower and regulatory pathways can move faster, alongside the company's established blockbuster portfolio. The approach diversifies approval risk and supports long-term pipeline optionality without requiring blockbuster-scale commercial launches for each asset.

On the acquisition front, AbbVie agreed to acquire Apogee Therapeutics in an all-cash deal valued at approximately $10.9 billion, described as the company's largest buyout in more than five years. The transaction reflects continued external business development as a complement to internal pipeline work, though AbbVie slightly trimmed its 2026 adjusted EPS guidance to account for the deal costs.

Readers tracking the broader pattern of pharma M&A activity can find additional context in the Energy, Pharma & Tech Acquisition Wave theme.

Ownership Structure and Market Positioning

Institutional investors hold approximately 70.23% of AbbVie shares, reflecting deep integration into large-cap healthcare index funds and active institutional mandates.

This concentration of ownership is a structural characteristic with practical implications: it tends to moderate extreme intraday volatility while also meaning that large index rebalancing or sector rotation events can produce synchronized positioning shifts.

For leveraged traders, the high institutional float also generally supports tighter bid-ask spreads and greater intraday liquidity compared with smaller-cap healthcare names.

Despite the Q2 earnings beat and raised revenue guidance, AbbVie's stock pulled back following results, a divergence between fundamental improvement and price action that traders following the name should note when calibrating near-term volatility assumptions.

Last updated: 2026-08-15

Key Insights

AbbVie's Q2 2026 results demonstrated revenue growth of 10.2% on a reported basis, reaching $16.99 billion, with adjusted EPS of $3.65, evidence that the immunology franchise continues to drive near-term cash generation even as longer-term pipeline transition remains the central investor debate.
The announced $10.9 billion all-cash acquisition of Apogee Therapeutics, described by Reuters as AbbVie's largest buyout in more than five years, signals active pipeline investment in inflammation biology and marks a significant capital allocation decision that trimmed near-term profit guidance.
AbbVie's full-year 2026 revenue guidance of approximately $67.6 billion reflects management confidence in core product momentum, while the simultaneous EPS guidance trim after the Apogee deal illustrates the classic pharma trade-off between near-term earnings and long-term pipeline durability.
Institutional ownership at approximately 70.23% of shares indicates that ABBV is primarily held by large funds whose positioning can amplify price moves around earnings releases, FDA decisions, and major M&A announcements, creating structured volatility events that CFD traders can plan around.
The FDA approval of Decnupaz for blastic plasmacytoid dendritic cell neoplasm, a very rare blood cancer, reflects AbbVie's strategy of pursuing orphan-disease designations to diversify revenue beyond its core immunology products and extend its addressable market.

Key Financials

Audited · SEC filings

Reported figures from the company’s latest SEC filings — each linked to its source filing and period.

$16.99B

Quarterly revenue

Q2 2026 · SEC 10-Q

$3.61B

Net income

Q2 2026 · SEC 10-Q

~74.7%

Gross margin

Q2 2026 · SEC 10-Q

$2.03

Diluted EPS

Q2 2026 · SEC 10-Q

~ Computed from two figures in the same filing — gross margin is revenue minus the reported cost of revenue, for filers who tag the cost line rather than gross profit.

Quarterly revenue

$19B

$15B

$12B

$13.34BQ1 2025

$15.42BQ2 2025

$15.78BQ3 2025

$16.62BQ4 2025

$15.00BQ1 2026

$16.99BQ2 2026

Figures are from the company’s audited SEC filings; each carries its filing source and period. Not investment advice.

Machine-readable table — same figures, per-metric source

Metric	Value	Source
Quarterly revenue (Q2 2026)	$16.99B	SEC 10-Q
Net income (Q2 2026)	$3.61B	SEC 10-Q
Gross margin (Q2 2026)	74.7%	SEC 10-Q
Diluted EPS (Q2 2026)	$2.03	SEC 10-Q

How Does ABBV Compare to Pharma and Biotech Peers?

Revenue Scale and Competitive Tier

AbbVie's full-year 2026 revenue guidance of approximately $67.6 billion positions it within a narrow tier of U.S. pharmaceutical companies capable of generating revenue at that scale.

Direct comparators include diversified healthcare conglomerates such as Johnson & Johnson and large-cap biotech leaders such as Amgen Inc. and Gilead Sciences.

While each of these companies operates across multiple therapeutic categories, the specific revenue architecture differs materially, a distinction that carries implications for risk profile, valuation multiples, and price sensitivity to individual product performance.

At approximately $67.6 billion in guided annual revenue, AbbVie generates scale comparable to the upper tier of U.S. pharmaceutical peers, but the composition of that revenue is more concentrated than most.

Strong immunology drug sales drove the Q2 2026 beat and remain the dominant segment by a wide margin, a characteristic that separates AbbVie's revenue profile from more evenly distributed competitors.

Therapeutic Focus vs. Peer Diversification

Unlike Johnson & Johnson, which distributes revenue across medtech, consumer health, and pharmaceuticals, or Amgen, whose biologics portfolio spans oncology, cardiovascular, and inflammation, AbbVie's revenue architecture is anchored heavily in immunology and specialty therapeutics.

This concentration produces high revenue-per-product metrics and deep expertise in a category where pricing power and patient retention rates are relatively durable.

The trade-off is greater exposure to pipeline-specific risks: a regulatory setback or competitive displacement in immunology carries more weight for AbbVie than a comparable event would for a peer with broader therapeutic distribution.

The Apogee Therapeutics acquisition, an all-cash transaction valued at approximately $10.9 billion and described as AbbVie's largest buyout in more than five years, reinforces this orientation.

Rather than signaling diversification away from inflammation and immunology, the deal deepens AbbVie's position in that domain, directly competing with Amgen's biologics franchise and other large-cap biotechs investing in next-generation mechanisms. The strategic posture is category leadership through consolidation, not therapeutic breadth.

Oncology Expansion and the Gap with Peers

AbbVie's oncology footprint is expanding but remains smaller relative to peers whose portfolios are more evenly distributed across therapy areas. The FDA approval of Decnupaz for blastic plasmacytoid dendritic cell neoplasm marks a tangible step in building oncology credibility, particularly in rare blood cancers where competitive density is lower.

However, immunology continues to account for the dominant share of revenue, and closing the oncology gap with more oncology-heavy peers requires sustained regulatory output and commercial execution over multiple product cycles.

Traders monitoring multi-sector earnings dynamics can reference the Q2 Earnings Beat Blue-Chip Surge theme for broader context on how large-cap healthcare names have been received relative to other sectors this cycle.

Institutional Ownership and Index Flow Dynamics

Institutional investors hold approximately 70.23% of AbbVie shares, a level consistent with other large-cap healthcare names that anchor sector ETFs and index funds. This ownership structure has a practical consequence for price dynamics: a meaningful portion of ABBV's trading flows reflects sector-level allocation decisions rather than purely company-specific fundamentals.

Rotation into or out of healthcare as a sector, driven by macro variables such as rate expectations, defensive positioning, or sector ETF rebalancing, will affect ABBV alongside peers, regardless of idiosyncratic earnings performance.

This dynamic distinguishes AbbVie from smaller or less liquid biotech names where institutional ownership is lower and price discovery is more directly tied to individual catalysts.

For a leveraged trader, it means that ABBV can experience sector-driven drawdowns or rallies that diverge from its underlying fundamental trajectory, a factor worth incorporating into position sizing and timing decisions.

Why Trade ABBV? Catalysts, Risks, and the 2026 Thesis

AbbVie enters the second half of 2026 with a set of competing forces that make it a structurally interesting instrument for active traders: a revenue engine outperforming expectations, a large acquisition creating near-term earnings drag, a pipeline dependent on a concentrated set of products, and a share price that pulled back despite a fundamentally positive earnings print.

Each of these dynamics has price-moving implications that extend well beyond the next quarterly report.

The Immunology Bull Case

The core long thesis rests on franchise momentum. Q2 2026 revenue of $16.99 billion grew approximately 10% year-over-year, with strong immunology drug sales identified as the primary driver of the earnings beat.

Management's decision to raise full-year 2026 revenue guidance to approximately $67.6 billion, following a quarter that already exceeded estimates, signals confidence that near-term demand for the immunology portfolio remains durable.

For a company operating at that revenue scale, an upward guidance revision is a meaningful signal: it implies that volume trends, pricing dynamics, and channel inventory levels all support sustained demand through year-end.

The Q2 print placed AbbVie in the category of large-cap names delivering genuine operating outperformance in the current earnings cycle, a pattern tracked more broadly in the Q2 Earnings Beat Blue-Chip Surge theme.

The Apogee Acquisition: Pipeline Catalyst and EPS Headwind

The $10.9 billion all-cash acquisition of Apogee Therapeutics, AbbVie's largest buyout in more than five years, introduces a capital allocation tension that traders must price explicitly.

The strategic logic is clear: external business development supplements an internal pipeline that faces long-term concentration risk, and Apogee adds early-stage immunology assets that could extend the franchise runway beyond current products.

The near-term cost is equally clear. AbbVie trimmed its 2026 adjusted EPS guidance following the deal announcement. In a market that prices large-cap pharma partly on earnings predictability, any downward EPS revision, even one driven by a strategically sound acquisition, creates a window of price pressure.

Traders positioning around acquisition-driven repricing events can find relevant context in the Energy, Pharma & Tech Acquisition Wave theme.

Pipeline Concentration: The Structural Risk

Pipeline concentration is AbbVie's most consistently cited structural risk. Revenue dependence on a limited number of products means that FDA decisions, patent litigation outcomes, and biosimilar entry timelines each carry outsized price impact. A single adverse ruling or an accelerated biosimilar launch schedule can reset revenue projections across multiple forward periods simultaneously.

This dynamic makes ABBV unusually reactive to regulatory calendars and litigation dockets, event types that often generate sharp intraday moves suited to leveraged CFD positioning.

For leveraged traders, this concentration profile cuts both ways: positive pipeline catalysts can produce rapid upside repricing, while adverse outcomes compress valuation multiples quickly. Sizing positions with that asymmetry in mind is essential.

Macro Positioning: Defensive Capital Flows

Healthcare's traditional defensive characteristics have become more relevant as tech-sector volatility has drawn investor attention. Investors were warming to healthcare stocks amid tech-trade turbulence during the Q2 2026 reporting period, a rotation pattern that can generate demand for large-cap pharma names independent of company-specific fundamentals.

With the VIX at 14.63 as of mid-August 2026 and the 10-year Treasury yield at 4.63%, the macro backdrop presents a moderate-risk environment where sector rotation into defensive positions remains a credible scenario during periods of broad equity stress.

The Post-Earnings Pullback Pattern

The clearest tactical signal from Q2 2026 is the disconnect between operating results and share price. AbbVie beat estimates, raised revenue guidance, and still saw its stock pull back. The mechanism is instructive: acquisition financing costs, near-term EPS dilution, and valuation-level expectations can dominate even a strong fundamental print in the short window following results.

Traders who model event-driven positioning around earnings dates should price in this gap between headline beat and price reaction, the market's forward-looking repricing of EPS trajectory can overwhelm trailing operating strength.

Detailed leverage scenarios for the Q2 print are available in the AbbVie Q2 2026 Earnings Beat analysis.

Watchlist Assessment

ABBV presents a layered opportunity set as of August 2026. The immunology franchise provides a durable near-term revenue floor. The Apogee acquisition introduces a defined EPS headwind with a finite duration. Pipeline concentration creates a recurring event calendar with binary price outcomes. Macro rotation dynamics offer a tactical entry rationale during tech-driven risk-off episodes.

Taken together, these factors support including ABBV on an active trading watchlist, with position sizing calibrated to the stock's tendency to gap sharply on regulatory and acquisition-related catalysts.

Valuation & peers

Multiples vs peers + third-party analyst targets

Peer Valuation Comparison

How this stock trades versus comparable listed companies on trailing valuation multiples.

Company	Market cap	P/E	P/S
AbbVie Inc. · ABBV	$468.2B	74.7x	7.3x
Johnson & Johnson · JNJ	$651.3B	31.2x	6.7x
Merck & Co., Inc. · MRK	$376.8B	121.1x	5.7x
UnitedHealth Group Incorporated · UNH	$354.3B	25.1x	0.8x
Novartis AG · NVS	$301.9B	24.2x	5.5x
AstraZeneca PLC · AZN	$257.3B	24.9x	4.2x

Third-party ratios (FMP), trailing twelve months. Multiples vary by data window; a negative or absent P/E means the company is loss-making. Not investment advice.

Analyst Price Targets

Buy

Wall Street sell-side analysts’ consensus 12-month price target and rating for this stock.

Consensus target

$285.92+7.7%

Target range

$235.00 – $303.00

Price-target coverage

17 analysts

Analyst ratings (42)

Buy 30Hold 11Sell 1

Targets by firm

Latest target from each of the 13 firms whose call was reported in the past 180 days. Each row links to the report.

Firm	Target	vs current
Piper Sandler2026-08-20 · TheFly	$303.00	+14.2%
Wells Fargo2026-08-17 · TheFly	$300.00	+13.0%
Wolfe Research2026-08-13 · TheFly	$300.00	+13.0%
Guggenheim2026-08-04 · TheFly	$288.00	+8.5%
Morgan Stanley2026-08-03 · TheFly	$296.00	+11.5%
Canaccord Genuity2026-08-03 · StreetInsider	$290.00	+9.3%
Barclays2026-07-29 · TheFly	$300.00	+13.0%
UBS2026-07-13 · TheFly	$260.00	-2.0%
BMO Capital2026-07-13 · TheFly	$300.00	+13.0%
RBC Capital2026-07-10 · StreetInsider	$280.00	+5.5%
HSBC2026-07-06 · TheFly	$300.00	+13.0%
Cantor Fitzgerald2026-07-06 · TheFly	$265.00	-0.2%
Evercore ISI2026-05-15 · TheFly	$235.00	-11.5%

Source: aggregated sell-side analyst consensus · as of 2026-08-23. These are third-party analyst opinions — not CoinUnited’s view, not a price prediction, and not investment advice.

Scenario calculator

Pick a third-party reference level and see what it implies at leverage. Reference levels only - not a CoinUnited forecast.

Scenario price

$265.41

+0.0% vs current

Your margin (USD)Leverage

Position size $100,000.00

P&L at this scenario (long)

+$0.00

Loss if liquidated -$1,000.00 (the full margin)

Liquidation price (long): $262.75 — a move of -1.0%

Trade ABBV

Simplified: excludes fees, funding and slippage. Reference levels are third-party marks (CoinUnited daily kline; aggregated sell-side analyst targets), not forecasts. Leverage magnifies losses as much as gains - at high leverage a small adverse move liquidates the position. Not investment advice.

Catalysts & news

Dated third-party developments · newest first

Catalyst Timeline

Dated third-party developments that move the stock — newest first, each classified bullish or bearish and linked to its source.

2026-10-29
Next quarterly earnings◆ Scheduled
Next scheduled quarterly earnings report (2026-10-29). Revenue, margins and guidance are the near-term driver; the outcome is not known in advance.
Finnhub
2026-05-27
FDA approves AbbVie BPDCN cancer drug▲ Bullish
May 27 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved AbbVie's (ABBV.N) drug to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN), ‌a very rare type of blood cancer.
Reuters
2026-04-23
Manufacturing requests may delay approval to 2027▼ Bearish
He also mentioned that requests related to manufacturing may have postponed approval until 2027. AbbVie clarified that the regulatory agency did not express any concerns regarding the treatment's safety or effectiveness and did not request…
Reuters
2025-07-21
Jury orders Revance to pay Allergan $56 million▲ Bullish
On July 21 (Reuters) - A jury in Delaware has determined that Revance Therapeutics must pay AbbVie’s (ABBV.N) Allergan Inc $56 million, concluding that Revance's wrinkle-reducing treatment, Daxxify, infringes on Allergan's patents…
Reuters
2025-05-14
AbbVie receives FDA approval for lung cancer drug▲ Bullish
May 14 (Reuters) - AbbVie announced on Wednesday that the U.S. Food and Drug Administration has granted approval for its medication aimed at treating adult patients with a specific type of lung cancer who have previously undergone…
Reuters
2025-04-25
AbbVie raises 2025 earnings guidance▲ Bullish
The drugmaker raised its 2025 adjusted earnings by 10 cents to a range of $12.09 to $12.29 a share. That 'does not reflect any trade policy shifts, including pharmaceutical sector tariffs, that could impact AbbVie's business,' according to…
Bloomberg

Machine-readable table — same developments, with source

Recent third-party developments classified bullish / bearish for the stock; verbatim, sourced.

Date	Development	Direction	Source
2026-10-29	Next scheduled quarterly earnings report (2026-10-29). Revenue, margins and guidance are the near-term driver; the outcome is not known in advance.	◆ Scheduled	Finnhub
2026-05-27	May 27 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved AbbVie's (ABBV.N) drug to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN), ‌a very rare type of blood cancer.	▲ Bullish	Reuters
2026-04-23	He also mentioned that requests related to manufacturing may have postponed approval until 2027. AbbVie clarified that the regulatory agency did not express any concerns regarding the treatment's safety or effectiveness and did not request…	▼ Bearish	Reuters
2025-07-21	On July 21 (Reuters) - A jury in Delaware has determined that Revance Therapeutics must pay AbbVie’s (ABBV.N) Allergan Inc $56 million, concluding that Revance's wrinkle-reducing treatment, Daxxify, infringes on Allergan's patents…	▲ Bullish	Reuters
2025-05-14	May 14 (Reuters) - AbbVie announced on Wednesday that the U.S. Food and Drug Administration has granted approval for its medication aimed at treating adult patients with a specific type of lung cancer who have previously undergone…	▲ Bullish	Reuters
2025-04-25	The drugmaker raised its 2025 adjusted earnings by 10 cents to a range of $12.09 to $12.29 a share. That 'does not reflect any trade policy shifts, including pharmaceutical sector tariffs, that could impact AbbVie's business,' according to…	▲ Bullish	Bloomberg

Key Takeaways

Last updated: 2026-07-31

•AbbVie trimmed 2026 EPS guidance to $13.87–$14.07 (from $13.91–$14.11) due to $0.58/share cumulative IPR&D charges, despite beating Q2 EPS at $3.65.
•Leverage risk is elevated: a 50x long ABBV CFD opened at the day's high of $259.93 is already deeply offside at $251.05 — position sizing and stops are critical.
•Underlying EPS power ex-IPR&D (~$14.37–$14.57) is significantly above headline guidance, creating a potential valuation rebound thesis if pipeline investments materialize.
•Pharma peers (Merck, Pfizer, J&J) face sympathy sector pressure; the healthcare ETF absorbs ABBV's drag, but macro indices (US500, US100) see minimal spillover.
•Future IPR&D charges remain unforecastable per management — expect continued guidance volatility around the Apogee Therapeutics deal closing in Q3 2026.

Latest Pulses

2026-07-31StocksBearish

ABBV

AbbVie 2026 Guidance Trim: $13.87–$14.07 EPS Target Masks Stronger Underlying Earnings — ABBV CFD Leverage Scenarios

AbbVie Inc. has updated its full-year 2026 adjusted EPS guidance to $13.87–$14.07 per share, trimmed from a prior range of $13.91–$14.11, according to the company's Q2 2026 earnings release. The revis

2026-07-31StocksBearish

ABBV

AbbVie Q2 2026 Earnings Beat: $3.65 EPS & $16.99B Revenue — ABBV CFD Leverage Scenarios & Pharma Sector Impact

AbbVie Inc. reported Q2 2026 non-GAAP EPS of $3.65, beating consensus by $0.04, alongside revenue of $16.99B that exceeded estimates by approximately $230M. As reported by Seeking Alpha and confirmed

2026-06-22StocksVolatile

ABBV

AbbVie's $10.9B Apogee Acquisition: Leverage Scenarios, Biotech Repricing & ABBV CFD Outlook

According to a PR Newswire press release, AbbVie (NYSE: ABBV) has announced a definitive agreement to acquire Apogee Therapeutics (NASDAQ: APGE) for approximately $10.9 billion in cash, at $135.11 per

2026-06-20StocksBullish

ABBV

AbbVie Nears $10.9B All-Cash Takeover of Apogee Therapeutics — Leverage Scenarios & Biotech Repricing

According to reporting attributed to the Financial Times and Bloomberg, AbbVie Inc. (ABBV) is closing in on an all-cash acquisition of Apogee Therapeutics (APGE) valued at approximately $10.9 billion.

View all ABBV pulses

Ownership

Top institutional holders (SEC Form 13F)

Top Institutional Holders

SEC 13F

The largest institutional shareholders, from SEC Form 13F filings — who holds the stock and how much.

Institution	Shares	Value	% of shares
BlackRock, Inc.	150.7M	$32.8B	8.53%
Vanguard Capital Management LLC	114.9M	$25.0B	6.50%
State Street Corp.	81.2M	$17.7B	4.60%
JPMorgan Chase & Co.	56.7M	$12.1B	3.21%
Vanguard Portfolio Management LLC	49.5M	$10.8B	2.80%
Geode Capital Management, LLC	46.7M	$10.1B	2.64%
Morgan Stanley	38.0M	$8.3B	2.15%
Capital Research Global Investors	31.3M	$6.8B	1.77%
Bank of America Corp.	23.9M	$5.2B	1.35%
FMR LLC	21.8M	$4.7B	1.23%

Source: SEC Form 13F filings · 4046 institutional holders · as of 31-MAR-2026. 13F data is quarterly and lagged (filed ~45 days after quarter-end) and covers US institutional managers (>$100M AUM) only — not insiders, retail, or foreign holders. Not investment advice.

How to trade it

Trading stock CFDs on CoinUnited + strategy

Trading Regime Status

Leverage

1000x

(Max on CoinUnited.io)

Volatility

Normal

(2.39% 24h)

How the ABBV CFD works

Before you trade, understand exactly what you get, what you don't, and where the risk sits.

What you buy

Price exposure to the ABBV reference (a synthetic CFD) that tracks the CoinUnited reference up and down.

What you do NOT get

It is not equity: no shares, no voting rights; dividends are reflected as an adjustment, not paid to you.

Basis / session risk

The CoinUnited reference tracks the share price but can differ from the exchange price; extended-hours liquidity is thinner.

Leverage illustration: with $100 margin at 1000× leverage you open a $100,000 notional position; if price moves against you to the liquidation level the position is force-closed. High leverage magnifies both profit and liquidation risk.

Trading conditions on CoinUnited

Fee schedule as of 2026-08-19

Trading fee: 0.070%
Trading hours: Market session
Maximum leverage: 1000x

See the full fee schedule →

Trading ABBV CFDs on CoinUnited.io

Leverage Mechanics and Position Sizing

The leverage available on ABBV CFDs fundamentally changes the arithmetic of every trade. A trader allocating $500 in margin at 1000x leverage controls $500,000 in notional exposure. At that level, a 1% move in ABBV's price produces a $5,000 gain or loss, ten times the initial margin. A 0.1% adverse move wipes out $500, eliminating the position entirely if no buffer is held.

This relationship makes position sizing and stop placement the most consequential pre-trade decisions, not entry price. The worked example below illustrates the structure:

Margin	Leverage	Notional Exposure	1% Move P&L	0.1% Move P&L
$100	100x	$10,000	±$100	±$10
$500	200x	$100,000	±$1,000	±$100
$500	1000x	$500,000	±$5,000	±$500
$1,000	500x	$500,000	±$5,000	±$500

Note that multiple leverage and margin combinations can produce identical notional exposure. Traders should select the combination that fits their risk tolerance and stop distance, not simply maximize leverage as a default.

With zero trading fees, the conventional spread-plus-commission friction that erodes entries and exits on traditional brokers is eliminated. This changes position-sizing logic: smaller, more frequent adjustments become viable, and scaling in or out of a position carries no incremental cost penalty. It does not, however, reduce the liquidation risk inherent to high leverage.

The 24/7 Access Advantage for Event-Driven Strategies

ABBV's underlying NYSE listing is accessible only from 9:30 am to 4:00 pm ET on weekdays, closing on US holidays and weekends. CoinUnited's ABBV CFD trades continuously, including Asia-session hours, weekends, and US market holidays. This structural difference has direct practical consequences for the types of events that drive ABBV price action.

AbbVie's Q2 2026 results, $3.65 adjusted EPS and $16.99 billion in revenue, both ahead of estimates, with full-year revenue guidance raised to approximately $67.6 billion, demonstrated that even a clear beat with raised guidance can produce a stock pullback.

Post-earnings direction depends on whether results clear not just consensus estimates but also prevailing forward expectations embedded in positioning.

The dynamics of Q2 multi-sector earnings are explored further in the Q2 Earnings Beat Blue-Chip Surge theme.

FDA approval announcements follow a similar pattern. The FDA's approval of AbbVie's Decnupaz is a category of news that can break outside NYSE hours. Traders holding ABBV CFDs are not locked into a position with no exit until Monday open or the next NYSE session, an advantage that equity holders in a standard brokerage account do not have.

M&A and Weekend Gap Risk

AbbVie agreed to acquire Apogee Therapeutics in an all-cash deal valued at approximately $10.9 billion, its largest buyout in more than five years. Transactions of this scale are frequently announced over weekends or after NYSE close, creating gap risk for equity holders who cannot exit until the next trading session.

AbbVie's decision to slightly trim its 2026 adjusted EPS guidance alongside the announcement illustrates that M&A news can carry mixed signals requiring rapid assessment.

CoinUnited's continuous session means ABBV CFD positions remain live and adjustable the moment any such announcement lands, regardless of day or time. This eliminates the forced holding period that amplifies gap risk for equity investors. Traders monitoring AbbVie's ongoing pipeline and business development activity should factor this structural advantage into their event-risk framework.

The broader pattern of pharma deal flow is covered in the Energy, Pharma & Tech Acquisition Wave theme.

Institutional Ownership and Intraday Liquidity Patterns

With approximately 70.23% of ABBV shares held by institutional investors, the stock's intraday behavior differs from retail-driven names. Index rebalancing dates, sector ETF flow events, and large-cap healthcare fund repositioning can produce distinct liquidity patterns, periods of concentrated volume or atypical spread behavior that may not reflect fundamental news.

Traders using high leverage should account for this when selecting entry timing. Sizing into a position during a period of institutional-driven flow at extreme leverage amplifies the risk that a short-term technical dislocation triggers liquidation before the underlying thesis plays out.

At lower leverage multiples, wider stops and longer time horizons become more viable relative to the 1000x maximum available.

⚡1000x💰0% Fee⏱️10s Start🌐24/7

Ready to Trade ABBV?

Up to 1000x leverage

Trade ABBV Now

Understand the risks

Read before trading

Trading Risks

An honest, up-front list of the risks — both out of respect for the trader and as a YMYL compliance requirement.

Leverage / Liquidation

High leverage means a small adverse move can trigger forced liquidation and loss of your full margin.

High-valuation volatility

A high P/E stock is very sensitive to interest-rate and narrative shifts; swings can be large.

Session gaps

After-hours and weekend gaps; extended-hours liquidity is thinner than the regular session.

Basis risk

The CFD reference price can diverge from the exchange execution price.

Earnings volatility

Price swings widen around earnings dates and other scheduled disclosures.

Regulatory / event

Recalls, policy changes, or company-specific events can cause sharp moves.

Reference

FAQ & glossary

Frequently Asked Questions

AbbVie topped second-quarter 2026 estimates primarily on strong immunology drug sales, posting adjusted earnings of $3.65 per share on revenue of $16.99 billion, which represented roughly 10.2% reported revenue growth year over year. The result confirmed that the company's immunology franchise remained the core engine of near-term performance. Despite the beat, the stock pulled back after results were released. The most commonly cited explanation is that the announced acquisition of Apogee Therapeutics, valued at approximately $10.9 billion, prompted AbbVie to trim its 2026 adjusted EPS guidance to absorb acquisition-related costs. Investors weighed the near-term profit dilution against the long-term pipeline rationale, and the market's reaction reflected that tension rather than any deterioration in the underlying business. This kind of post-earnings pullback on an otherwise solid quarter is not unusual for large-cap pharmaceutical names when a major capital deployment is announced simultaneously. Traders monitoring ABBV CFDs on CoinUnited can observe these intraday moves around earnings releases without being constrained by traditional brokerage session windows.

Glossary

Key listed-stock and CFD terms, one line each — so the page is unambiguous for both readers and AI answer engines.

Stock CFD	A contract for difference on a share price — price exposure only, not ownership of the underlying shares.
Extended hours	Pre-market and after-hours trading outside the exchange’s regular session.
Basis risk	The risk that the CFD reference price and the exchange execution price do not move in step.
P/E	Price-to-earnings ratio = share price ÷ earnings per share; a common valuation gauge.
Gross margin	Gross profit ÷ revenue; reflects product-level profitability.
EPS	Earnings per share = net income ÷ diluted shares outstanding.

symbol

ABBV

Markets

Stocks

Sector

Healthcare

CU Product Code

ABBV

Source Map

Every figure on this page traces to a primary or named third-party source. "As of" dates the source; "last checked" dates our most recent read of it.

Every figure here is also published as machine-readable data, and re-checked on a schedule so a stale one shows up as stale. View the raw data

Field	Value	Source	As of	Last checked
Reference price	live	CoinUnited stock CFD reference (live)	—	—	—
Market cap	$469B	CoinUnited reference x SEC shares	2026-08-23	2026-08-23	—
P/E	~112.5	CoinUnited reference / SEC annual EPS	—	2026-08-23	—
52-week range	$193.25 – $270.37	CoinUnited daily kline	—	2026-08-23	—
Next earnings	2026-10-29	Finnhub	—	2026-08-23	—
Quarterly revenue	$16.99B	SEC 10-Q	Q2 2026	2026-08-23	View
Net income	$3.61B	SEC 10-Q	Q2 2026	2026-08-23	View
Gross margin	74.7%	SEC 10-Q	Q2 2026	2026-08-23	View
Diluted EPS	$2.03	SEC 10-Q	Q2 2026	2026-08-23	View
Institutional ownership	10 top holders	SEC Form 13F	31-MAR-2026	2026-08-23	View
Analyst price targets	$285.92 consensus	Aggregated sell-side analyst consensus	2026-08-23	2026-08-23	—
Peer valuations	6 peers	Third-party ratios (FMP), trailing twelve months	2026-08-23	2026-08-23	—
Founded	2012	Wikidata	—	2026-08-23	—
Headquarters	North Chicago	Wikidata	—	2026-08-23	—
CEO	Robert A. Michael	Wikidata	—	2026-08-23	—
Industry	biotechnology, pharmaceutical industry	Wikidata	—	2026-08-23	—
CoinUnited product	Stock CFD — price exposure, not equity (no voting; dividends reflected as adjustment); leverage available, extended/24h	CoinUnited product terms	—	2026-08-23	—

About the Author

CoinUnited.io Research Team

This page is compiled by CoinUnited.io's research team: analysts covering listed equities and global markets, working from primary filings and named third-party data rather than opinion.

Our Research Methodology

Every figure is traced to a primary or named third-party source and dated: financial statements from the company's SEC filings, institutional ownership from Form 13F, analyst targets from aggregated third-party coverage, and market data from the CoinUnited reference price. The Source Map on this page lists each one with its source and the date we last checked it.

Disclaimer: content is for informational and educational purposes only and is not personalized financial advice. A stock CFD carries significant risk and provides price exposure only, not equity ownership. Always conduct your own research and consult a qualified financial advisor.

Disclaimers & References

Important Risk Disclaimer

A CoinUnited stock CFD gives price exposure to AbbVie Inc. only, not equity ownership: no shareholder voting rights, no dividends, and no settlement in the underlying share.

Leverage magnifies losses as well as gains, and a position can be liquidated long before the underlying share price recovers. The underlying listing trades on exchange hours, so the reference price can gap between sessions.

Users should conduct their own research and consult with qualified financial professionals before making any investment decisions. The creators and operators of this platform assume no responsibility for any financial losses or other damages that may result from reliance on the information provided.

Leveraged trading is extremely risky and you may lose your entire deposit.

Methodology Overview

Figures on this page are compiled from primary and named third-party sources, not produced by a forecasting model. Each one carries its source and date in the Source Map above.

Financial statements: the company's own SEC filings (10-K / 10-Q), read from XBRL
Market data: the CoinUnited reference price and daily closes
Institutional ownership: SEC Form 13F quarterly filings
Analyst targets: aggregated third-party sell-side coverage — third-party opinion, not CoinUnited's view
Peer multiples: third-party trailing-twelve-month ratios

CoinUnited does not publish a price forecast or target for AbbVie Inc..

Last methodology review:

Ready to Start Trading AbbVie Inc.?

Join thousands of traders and start your AbbVie Inc. trading journey today. Get access to advanced trading tools and competitive fees.

Trade ABBV/USDT Sign Up Now

ABBV

AbbVie Inc.

$265.40

▲+1.23%24h

24h Low24h High

$260.47$266.83

Bid

$265.21

Ask

$265.60

Trade Now

Up to 1000x leverage•Tiered fees

Live from CoinUnited.io

ABBV

$265.40+1.23%

Trade Now

Navigate to Other Instruments

Quick Links

Position Calculator

AbbVie Inc.

Key facts & how to trade

Access & Tradability Comparison

Key Facts

Price & Market Structure

Company & financials

What Is AbbVie Inc. (ABBV)?

Corporate Scale and Revenue Architecture

Pipeline Activity and Regulatory Milestones

Ownership Structure and Market Positioning

Key Insights

Key Financials

Quarterly revenue

How Does ABBV Compare to Pharma and Biotech Peers?

Revenue Scale and Competitive Tier

Therapeutic Focus vs. Peer Diversification

Oncology Expansion and the Gap with Peers

Institutional Ownership and Index Flow Dynamics

Why Trade ABBV? Catalysts, Risks, and the 2026 Thesis

The Immunology Bull Case

The Apogee Acquisition: Pipeline Catalyst and EPS Headwind

Pipeline Concentration: The Structural Risk

Macro Positioning: Defensive Capital Flows

The Post-Earnings Pullback Pattern

Watchlist Assessment

Valuation & peers

Peer Valuation Comparison

Analyst Price Targets

Targets by firm

Scenario calculator

Catalysts & news

Catalyst Timeline

Key Takeaways

Latest Pulses

AbbVie 2026 Guidance Trim: $13.87–$14.07 EPS Target Masks Stronger Underlying Earnings — ABBV CFD Leverage Scenarios

AbbVie Q2 2026 Earnings Beat: $3.65 EPS & $16.99B Revenue — ABBV CFD Leverage Scenarios & Pharma Sector Impact

AbbVie's $10.9B Apogee Acquisition: Leverage Scenarios, Biotech Repricing & ABBV CFD Outlook

AbbVie Nears $10.9B All-Cash Takeover of Apogee Therapeutics — Leverage Scenarios & Biotech Repricing

Ownership

Top Institutional Holders

How to trade it

Trading Regime Status

How the ABBV CFD works

Trading conditions on CoinUnited

Trading ABBV CFDs on CoinUnited.io

Leverage Mechanics and Position Sizing

The 24/7 Access Advantage for Event-Driven Strategies

M&A and Weekend Gap Risk

Institutional Ownership and Intraday Liquidity Patterns

Ready to Trade ABBV?

Understand the risks

Trading Risks

Reference

Frequently Asked Questions

1. What drove AbbVie's Q2 2026 earnings beat and why did the stock pull back afterward?

2. How does AbbVie's $10.9 billion Apogee Therapeutics acquisition affect its 2026 profit guidance and long-term pipeline?

3. What is AbbVie's full-year 2026 revenue guidance and what products underpin that forecast?

4. What was the FDA-approved AbbVie drug Decnupaz and what does that approval signal about the oncology pipeline?

5. How does trading ABBV CFDs on CoinUnited differ from buying ABBV shares on a traditional brokerage, especially around earnings nights and M&A announcements?

6. What are the main risk factors for holding an ABBV leveraged position — including biosimilar competition and pipeline concentration?

7. How does AbbVie's institutional ownership level influence its short-term price volatility and liquidity during sector rotation events?

8. How does AbbVie's immunology franchise compare to peers like Amgen and Johnson & Johnson in terms of revenue concentration risk?

9. How are AbbVie dividends handled when trading ABBV as a CFD on CoinUnited?

10. What does AbbVie's price-to-earnings (P/E) ratio tell you about how the market is valuing the stock relative to its pharma peers?

11. When are AbbVie's scheduled earnings dates, and how does volatility typically behave around those windows?

12. Can I trade ABBV CFDs on CoinUnited outside of U.S. stock market hours, and what gap risk should I be aware of?

13. How does leverage work for an ABBV CFD position on CoinUnited, and what triggers a liquidation?

14. What is basis risk when trading ABBV as a CFD, and how closely does the CoinUnited CFD price track the NYSE-listed share price?

15. What is AbbVie's dividend yield and payout history, and why do income-focused traders pay attention to it?

16. Is ABBV available to trade on CoinUnited for investors outside the United States, and are there regional eligibility restrictions?

17. How has AbbVie's revenue mix shifted since Humira lost U.S. patent exclusivity, and what does that mean for the company's near-term revenue stability?

18. What is AbbVie's debt profile, and does the company's leverage affect how the stock behaves during broad market rate cycles?

19. How does AbbVie's aesthetics segment — including Botox — contribute to overall revenue, and does it introduce different demand drivers than the pharmaceutical portfolio?

20. How do major FDA decisions on AbbVie pipeline assets affect intraday CFD price volatility, and how can CoinUnited's 24/7 trading help traders respond?

Glossary

symbol

Markets